Managing Partner, Chief Operating Officer SV Health Investors
Continued strong sector fundamentals, improving end markets, new product launches and healthy pipelines has led to a significant run up in valuations of private and public medtech assets. As a result, organizations have been adopting new and more advanced valuation techniques to appropriately evaluate potential acquisitions - both from the buy and sell side. Officials from some of the most successful medtech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive buy and sell side valuation for M&A and what challenges remain, including the following: -How are companies succeeding in competitive situations for attractive targets? -What are the right analytical tools for evaluating complex economics globally, including payer dynamics and commercial risks? -What levels of strategic and operational diligence are required to properly value? -How is the capital markets environment---cheap credit, activist shareholders - affecting resource allocation for transformative M&A?